QTI QT IMAGING HOLDINGS, INC.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1844505 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY220.0%
TTM net income YoY8.2%
TTM EPS YoY58.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin40.4%
Operating margin-24.8%
Net margin-77.3%
FCF margin-48.2%
EBITDA margin-24.5%
Returns
ROE-2,125.0%
ROA-96.6%
ROIC (approx.)-98.7%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets92.7%
Debt / equity5.07x
Current ratio3.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-37.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $18.93M | $4.88M |
| Cost of revenue | $10.34M | $2.24M |
| Gross profit | $8.58M | $2.64M |
| R&D expense | $3.94M | $3.27M |
| SG&A expense | $9.09M | $11.55M |
| Operating income | -$4.44M | -$12.18M |
| Pretax income | -$21.08M | -$9.00M |
| Income tax | -$1,000 | -$16,000 |
| Net income | -$21.08M | -$8.98M |
| EBITDA | -$4.31M | -$11.95M |
| EPS (basic) | -2.01 | -2.13 |
| EPS (diluted) | -2.01 | -2.13 |
| Weighted avg. shares (diluted) | 10.48M | 6.66M |
| Balance sheet | ||
| Cash & equivalents | $10.41M | $1.17M |
| Receivables | $5.78M | $67,000 |
| Inventory | $5.03M | $3.14M |
| Current assets | $22.09M | $4.92M |
| PP&E, net | $318,000 | $196,000 |
| Total assets | $23.02M | $6.09M |
| Current liabilities | $7.87M | $9.79M |
| Long-term debt | $10.11M | $9.93M |
| Total debt | $10.11M | $9.93M |
| Total liabilities | $16.58M | $15.62M |
| Shareholders' equity | $6.45M | -$9.54M |
| Net debt | -$303,000 | $8.76M |
| Shares outstanding | 11.90M | 8.93M |
| Cash flow statement | ||
| Operating cash flow | -$8.96M | -$10.03M |
| Capital expenditure | $124,000 | $88,000 |
| Free cash flow | -$9.08M | -$10.12M |
| Investing cash flow | -$124,000 | -$88,000 |
| Financing cash flow | $18.35M | $11.13M |
| Depreciation & amortization | $131,000 | $231,000 |
| Stock-based compensation | $801,000 | $290,000 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.